Net Sales are expected to increase by 1.8 percent Y-o-Y (up 2.3 percent Q-o-Q) to Rs 6,848.5 crore, according to ICICI Securities.

Cipla set to launch key drugs Abraxane and Advair in FY26

Cipla's oncology drug Abraxane will be launched from its Goa facility while respiratory drug Advair will be rolled out from the New Jersey plant.

Multiple near-term challenges may hijack Cipla's growth trajectory

Cipla projects a mid-FY26 launch for Advair, while the release of Abraxane is contingent on regulatory clearance of the company's Goa facility. Respiratory drug Albuterol faces intensifying competition, while similar concerns loom over the blockbuster cancer drug Revlimid, whose patent is set to expire in 2026.

Cipla's strong US pipeline, steady Q4 earnings and hopes of easing regulatory snags drive bullishness

Cipla plans to launch 12 assets in peptides and complex generics space and 5 in the respiratory segment over FY25-27, which brokerages believe will secure its growth path for the next 3-4 years.

Cipla Q4 results preview: Revenue boost likely from strong US sales, net profit to jump from low base

Cipla's US sales likely to surge in Q4, driven by the contribution from Revlimid, along with a stable market share in Albuterol (respiratory drug) and an expansion in Lanreotide (hormonal drug) and Brovana (inhalation drug)

Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities

Net Sales are expected to decrease by 4.7 percent Y-o-Y (up 9.6 percent Q-o-Q) to Rs 6,290.9 crore, according to ICICI Securities.

Cipla Q1 PAT seen up 15.6% YoY to Rs 793.7 cr: Nirmal Bang

Net Sales are expected to increase by 14.8 percent Y-o-Y (up 7.5 percent Q-o-Q) to Rs 6.171.7 crore, according to Nirmal Bang.

Cipla Q4 preview: Robust domestic traction, gRevlimid sales likely to give earnings a big boost

Cipla Q4 preview: The company is expected to double its consolidated net profit to Rs 723.4 crore from Rs 362.07 crore in the year-ago quarter. It is also seen as the biggest beneficiary of a strong flu season in India

Cipla Q4 PAT seen up 58% YoY to Rs 6,485 cr: Nirmal Bang

Net Sales are expected to increase by 9.5 percent Y-o-Y (down 0.9 percent Q-o-Q) to Rs 57,594 crore, according to Nirmal Bang.

Cipla Q3 preview | Consolidated net profit likely to rise 22% YoY

Cipla’s generic version of Revlimid may reinforce sales in the US and improve the EBITDA margin on a yearly basis

Cipla Q3 PAT seen up 33.1% YoY to Rs 9,699 cr: Nirmal Bang

Net Sales are expected to increase by 16 percent Y-o-Y (up 8.3 percent Q-o-Q) to Rs 63,138 crore, according to Nirmal Bang.

Cipla Q2 preview | Consolidated net profit likely to rise 9% YoY

In the year-ago quarter, Cipla benefitted from the surge in sales of COVID-19-related drugs

Cipla Q1 Preview | Profit may decline 10% YoY on flat revenue

Brokerages expect a decline in domestic sales due to a high base of last year but a healthy YoY growth in the US, Europe and South Africa

Cipla Q1 PAT may dip 23.2% YoY to Rs 645 cr: Prabhudas Lilladher

Net Sales are expected to increase by 2.9 percent Y-o-Y (up 7.7 percent Q-o-Q) to Rs 5,665.5 crore, according to Prabhudas Lilladher.

Cipla Results Preview | Consolidated net profit may rise 47% on India ops

The company will report its March quarter numbers later today

Cipla Q4 PAT seen up 27.6% YoY to Rs 527.6 cr: Prabhudas Lilladher

Net Sales are expected to increase by 7 percent Y-o-Y (down 10 percent Q-o-Q) to Rs 4,930.6 crore, according to Prabhudas Lilladher.

Cipla Q3 PAT may dip 6.4% YoY to Rs 700.3 cr: Prabhudas Lilladher

Net Sales are expected to increase by 7.6 percent Y-o-Y (up 0.7 percent Q-o-Q) to Rs 5,560.6 crore, according to Prabhudas Lilladher.

Cipla Q2 PAT seen up 20.3% YoY to Rs 793.4 cr: Prabhudas Lilladher

Net Sales are expected to increase by 4 percent Y-o-Y (down 5.5 percent Q-o-Q) to Rs 5,169.7 crore, according to Prabhudas Lilladher.

Cipla Q1 PAT seen up 10.9% YoY to Rs 640.7 cr: KRChoksey

Net Sales are expected to increase by 18.5 percent Y-o-Y (up 11.8 percent Q-o-Q) to Rs 5,151.2 crore, according to KRChoksey.

Cipla Q1 PAT may dip 7.5% YoY to Rs 534.3 cr: ICICI Direct

Net Sales are expected to increase by 11 percent Y-o-Y (up 4.7 percent Q-o-Q) to Rs 4,822.4 crore, according to ICICI Direct.

Cipla Q4 PAT seen up 147.8% YoY to Rs. 609 cr: Sharekhan

Net Sales are expected to increase by 15 percent Y-o-Y (down 2.7 percent Q-o-Q) to Rs. 5,031.7 crore, according to Sharekhan.

Cipla Q3 PAT seen up 74.3% YoY to Rs. 612 cr: Yash Securities

Net Sales are expected to increase by 14 percent Y-o-Y (down 1.1 percent Q-o-Q) to Rs. 4985 crore, according to Yash Securities.

Cipla Q3 PAT seen up 77.2% YoY to Rs. 351 cr: Prabhudas Lilladher

Net Sales are expected to increase by 15.3 percent Y-o-Y (down 1.8 percent Q-o-Q) to Rs. 4,234.6 crore, according to Prabhudas Lilladher.

Cipla Q3 PAT seen up 73.2% YoY to Rs. 608.1 cr: ICICI Direct

Net Sales are expected to increase by 15.7 percent Y-o-Y (up 0.4 percent Q-o-Q) to Rs. 5,057.6 crore, according to ICICI Direct.

Cipla Q4 profit, revenue could decline due to high-base effect

At operating level, there could be a big fall on year-on-year basis, but the sequential decline may be much less compared to YoY.